Docket No.: HO-P02086US1 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

James R. Lupski et al.

Application No.: 10/021,955

Filed: December 13, 2001 Art Unit: 1637

For: DEFECTS IN PERIAXIN ASSOCIATED Examiner: S. Chunduru

WITH MYELINOPATHIES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Supplemental Information Disclosure Statement is filed more than three months after the U.S. filing date, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

I hereby certify that no item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application. The references are being submitted related to issues raised during the course of prosecution.

A copy of the references are listed on the PTO/SB/08 which is attached.

08/27/2004 CNGUYEN 00000078 10021955

01 FC:1806 180.00 OP

25436579.1

In accordance with 37 CFR 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Supplemental Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-2375, under Order No. HO-P02086US1. A duplicate copy of this paper is enclosed.

Dated:

Respectfully submitted,

Melissa L. Sistrunk

Registration No.: 45,579

FULBRIGHT & JAWORSKI L.L.P.

1301 McKinney, Suite 5100 Houston, Texas 77010-3095

(713) 651-5151

(713) 651-5246 (Fax)

Attorney for Applicant

lug. 25, 2004

PTO/SB/08A (10-01)
Approved for use through 10/31/2002.OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known				
Application Number	10/021,955			
Filing Date	December 13, 2001			
First Named Inventor	James R. Lupski			
Art Unit	1637			
Examiner Name	S. Chunduru			
Attorney Docket Number	HO-P02086US1			

U.S. PATENT DOCUMENTS					
Examiner Cite Initials* No.1	Document Number	Publication Date	Name of Patentee or Applicant	Pages, Columns, Lines, Where Relevant	
		Number-Kind Code ² (if known)	MM-DD-YYYY	of Cited Document	Passages or Relevant Figures Appear
	AA	US-5,599,920	02-04-1997	Patel, et al.	

1

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite ·No.1	Foreign Patent Document Country Code³-Number⁴-Kind Code⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
	CA	Kijima, Kazuki, et al; Periaxin mutation causes early-onset but slow-progressive Charcot-Marie-Tooth disease; J. Hum. Genet., (2004) Vol. 49, pp. 376-379.		
	СВ	Takashima, Hiroshi, et al.; Periaxin Mutations Caused a Broad Spectrum of Demyelinating Neuropathies; Ann. Neurol (2002), Vol. 51, pp. 709-715.		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

25436571.1 Examiner	Date Considered	
Signature		

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.